Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Blinded Drug

17 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Prevention

    COGALTE1621

    10/03/2016

    Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

    Treatment

    VICCURO16158

    09/07/2017

    A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (ANTI−PD-L1 Antibody) as Monotherapy and in Combination with Platinum-Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma

    Treatment

    VICCSAR15131

    09/01/2017

    A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma

    Treatment

    VICCHN16122

    07/25/2017

    A Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin plus Definitive Radiation Therapy) versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    Treatment

    VICCGYN16105

    06/26/2017

    Phase III Study of ADXS11-001 Administered Following Chemoradiation As Adjuvant Treatment For High Risk Locally Advanced Cervical Cancer

    Treatment

    VICCGI1721

    06/23/2017

    A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of AG-120 in Previously-Treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

    Treatment

    VICCURO16120

    05/15/2017

    A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy

    Treatment

    VICCNEU1688

    04/28/2017

    A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (Tumor O6-methylguanine DNA methyltransferase) Glioblastoma

    Treatment

    VICCBMT16110

    03/10/2017

    A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

    Treatment

    VICCBRE15147

    01/20/2017

    A Randomized Phase II Trial of Fulvestrant with or without Ribociclib (LEE011) After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Advanced Hormone Receptor Positive, HER2 Negative Breast Cancer

    Treatment

    ECOGNEUA221208

    01/18/2017

    Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis after Radiosurgery for Brain Metastases

    Treatment

    VICCBRE1642

    12/15/2016

    Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

    Treatment

    VICCTHO15115

    11/08/2016

    A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120 Mg Plus Bsc Vs. Placebo Plus Bsc For Tumour Control In Subjects With Well Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumours

    Treatment

    VICCBMT1610

    09/30/2016

    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

    Treatment

    VICCHN1574

    03/21/2016

    A Randomized, Multicenter, Double-Blind Phase 2 Study of Palbociclib plus Cetuximab versus Cetuximab for the Treatment of Human Papillomavirus -Negative, Cetuximab-Naive Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck After Failure of One Prior Platinum-Containing Chemotherapy Regimen

    Treatment

    VICCBRE1692

    09/01/2015

    Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

    Treatment

    VICCSAR1483

    02/26/2015

    SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas


    Print this page for your doctor